Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

med.uoeh-u.ac.jp Biological agents targeting tumour necrosis factor (TNF) have revolutionised the treatment of rheumatoid arthritis (RA) and clinical remission has become a realistic treatment goal.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

lumc.nl In rheumatoid arthritis (RA), it is becoming common to attempt to taper or stop medication, aiming for sustained drug-free remission (SDFR). Autoantibody seropositivity is a poor prognostic ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

That's the goal. And if we don't achieve that ... Like most other chronic inflammatory conditions, whether it's rheumatoid arthritis or Crohn's disease, it's a challenge. Once the body has ...

The technology was announced at the JP Morgan Healthcare Conference in San Francisco. In this project, the stakeholders aim to use a human reference genome to combine with patient data in order to try ...

Timely escalation to second-line disease-modifying drugs after treat-to-target methotrexate failure may not prevent the development of difficult-to-treat rheumatoid arthritis. Early treatment ...

8 There is a consensus that csDMARDs are the mainstay of RA treatment, and the 2019 update of the EULAR recommendations supported the use of methotrexate as the first-line DMARD. 8 If there is ...